Advancing disease-modifying therapies for Parkinson's disease: Current strategies and future directions.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing therapeutic strategies and mechanisms without systematic search methodology or new human clinical data.
PubMed 42582117 · doi:10.1016/j.xinn.2025.101112
What was done
This narrative review summarizes current and emerging disease-modifying therapeutic strategies for Parkinson's disease based on published literature and the authors' prior mechanistic research. Approaches discussed include passive immunization, small-molecule inhibitors, gene editing targeting α-synuclein aggregation, mitochondrial-targeted strategies, cell replacement therapy, and the receptor FAM171A2.
What was found
The abstract reports no numerical outcome data or trial statistics. It summarizes qualitative disease mechanisms and potential intervention points, noting that the authors recently identified FAM171A2 as a novel neuronal receptor for pathological α-synuclein that may serve as a target for disrupting transmission.
Why it matters
No approved therapy currently slows Parkinson's disease progression, leaving an urgent unmet need. Identifying and summarizing emerging targets, such as FAM171A2, helps map future translational research directions.
Limits
This is a narrative review with no systematic search methodology, meta-analysis, or primary clinical trial data reported in the abstract. No human sample sizes, effect sizes, or quantitative safety and efficacy metrics are provided.
Cited by
- supports No medications currently used to treat Parkinson's disease have been demonstrated to slow disease progression.